- Previous Close
3.5500 - Open
3.5500 - Bid 3.4500 x --
- Ask 3.5700 x --
- Day's Range
3.4700 - 3.6100 - 52 Week Range
2.1400 - 3.6100 - Volume
1,521,793 - Avg. Volume
1,272,157 - Market Cap (intraday)
720.547M - Beta (5Y Monthly) 1.17
- PE Ratio (TTM)
29.75 - EPS (TTM)
0.1200 - Earnings Date Aug 28, 2024
- Forward Dividend & Yield 0.18 (5.04%)
- Ex-Dividend Date Sep 4, 2024
- 1y Target Est
3.04
Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunology; serology and microbiology; and infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing services. It offers its service to private and public hospitals. The company was incorporated in 2020 and is headquartered in Clayton, Australia.
www.clinicallabs.com.au4,900
Full Time Employees
June 30
Fiscal Year Ends
Sector
Industry
Recent News: ACL.AX
View More
Performance Overview: ACL.AX
Trailing total returns as of 9/23/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACL.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACL.AX
View MoreValuation Measures
Market Cap
720.55M
Enterprise Value
1.00B
Trailing P/E
29.75
Forward P/E
19.34
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.03
Price/Book (mrq)
4.06
Enterprise Value/Revenue
1.45
Enterprise Value/EBITDA
5.91
Financial Highlights
Profitability and Income Statement
Profit Margin
3.44%
Return on Assets (ttm)
6.67%
Return on Equity (ttm)
13.84%
Revenue (ttm)
696.37M
Net Income Avi to Common (ttm)
23.93M
Diluted EPS (ttm)
0.1200
Balance Sheet and Cash Flow
Total Cash (mrq)
26.84M
Total Debt/Equity (mrq)
173.77%
Levered Free Cash Flow (ttm)
158.2M
Research Analysis: ACL.AX
View MoreCompany Insights: ACL.AX
ACL.AX does not have Company Insights